Orlistat and antisense-miRNA-loaded PLGA-PEG nanoparticles for enhanced triple negative breast cancer therapy. - Test2 - elhamkhani - TriplyDB

Orlistat and antisense-miRNA-loaded PLGA-PEG nanoparticles for enhanced triple negative breast cancer therapy.

Orlistat and antisense-miRNA-loaded PLGA-PEG nanoparticles for enhanced triple negative breast cancer therapy.

http://www.wikidata.org/entity/Q37013406

about

Gemcitabine and Antisense-microRNA Co-encapsulated PLGA-PEG Polymer Nanoparticles for Hepatocellular Carcinoma Therapy.Tumour biology of obesity-related cancers: understanding the molecular concept for better diagnosis and treatment.miRNA nanotherapeutics for cancer.Effects of Fatty Acid Synthase Inhibition by Orlistat on Proliferation of Endometrial Cancer Cell Lines.iRGD-functionalized PEGylated nanoparticles for enhanced colon tumor accumulation and targeted drug delivery.Fatty acid synthase (FASN) as a therapeutic target in breast cancer.Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells.Nanotechnology based approaches for detection and delivery of microRNA in healthcare and crop protection.Non-Viral Based miR Delivery and Recent Developments.

P2860

Q37550964-6909D883-B638-4253-828B-42FE103DAFB6 Q38953433-4C71D42E-0573-43E1-BDDD-BC11B2A5806C Q38999082-97DB89B7-DBEC-4BC5-B82C-6F7D474EA544 Q46547178-143B778F-A18D-4CBA-AD36-18D5B40CDE23 Q47815925-D87791AA-5BB6-4ED4-B70B-5A16284ECEC8 Q50044384-EC70BB6B-3646-4911-ACBD-2B39A239DBD0 Q50944315-35D7CD39-09C4-407F-A2CD-AF72381E85B4 Q52589516-32AF41D1-C893-492D-B808-D8B2799B424B Q54231141-AB33C8F4-362D-4CAF-BF62-52A4B93379A2

P2860

Orlistat and antisense-miRNA-loaded PLGA-PEG nanoparticles for enhanced triple negative breast cancer therapy.

http://www.wikidata.org/entity/Q37013406

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 January 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Orlistat and antisense-miRNA-l ...... egative breast cancer therapy.

@en

Orlistat and antisense-miRNA-l ...... egative breast cancer therapy.

@nl

type

label

Orlistat and antisense-miRNA-l ...... egative breast cancer therapy.

@en

Orlistat and antisense-miRNA-l ...... egative breast cancer therapy.

@nl

prefLabel

Orlistat and antisense-miRNA-l ...... egative breast cancer therapy.

@en

Orlistat and antisense-miRNA-l ...... egative breast cancer therapy.

@nl

P1433

Q37013406-BB5F47C9-2429-46EB-BBF2-DC490C4EE2E4

P1476

Q37013406-0693369F-135D-4E35-9E59-129BF09C83BA

P2093

Q37013406-6766CCBD-B1D4-4F9C-B992-58758FC07746

Q37013406-815B45D4-933A-4843-BD2A-8A8474F3A7C7

Q37013406-B390E7D0-5B53-4124-8589-27DF73BE62CD

P2860

Q37013406-0ABCD8BA-CC0C-468A-92E5-4D0C7523BAB8

Q37013406-0D4E7C4B-7E2F-4661-997B-02828A44BFFF

Q37013406-12DDF0D9-D68C-41C0-98D6-28917613780A

Q37013406-1B37294E-09A8-4D10-A9F9-4383FDC1A2C6

Q37013406-342A4030-9A54-4933-A0F0-9024B8650028

Q37013406-39FDDC40-6B26-4D2C-A768-DC866E21C744

Q37013406-3EE2DF69-E65C-49A8-B439-10E91669E196

Q37013406-52958341-80C0-4BE0-BF62-98E99E23764E

Q37013406-55935AF6-085C-4D2A-97CC-3FC42F6742ED

Q37013406-5CE47CFD-88C8-4262-8559-738141178E62

P304

Q37013406-F06EAAE6-FE75-4605-93F1-D2079A4DABB2

P31

Q37013406-355E5B9C-28B7-49D6-B26E-00AA65AAE574

P356

Q37013406-19D6CF83-D77B-4676-96D8-995E882BD172

P433

Q37013406-98430926-7BEF-45D8-8A52-300AB2EE7585

P478

Q37013406-C613BA1D-156B-41C4-BBD2-21B2DBD01932

P50

Q37013406-DDA596A9-DB0F-41BA-88B1-8E47774B82CF

P577

Q37013406-79D7D07A-ADFA-475C-8FED-1A7EB414CDC6

P5875

Q37013406-C691B768-BF07-492F-8D11-30158534F020

P698

Q37013406-26FB9861-F3D6-412C-A7C9-8D4259979ADB

P921

Q37013406-87454F0E-8BE4-4AD3-90F5-D037E793052E

P932

Q37013406-1CF71957-5FA0-4C92-B8E0-9F54A42DE00B

P356

P1433

P1476

Orlistat and antisense-miRNA-l ...... negative breast cancer therapy

@en

P2093

Aarohi Bhargava-Shah

http://www.w3.org/2001/XMLSchema#string

Kira Foygel

http://www.w3.org/2001/XMLSchema#string

Ramasamy Paulmurugan

http://www.w3.org/2001/XMLSchema#string

P2860

Polymer nanoparticles for drug and small silencing RNA delivery to treat cancers of different phenotypes

Global cancer statistics, 2012

Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival

Therapeutic nanoparticles for drug delivery in cancer

Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.

Polymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy.

Orlistat in the treatment of obesity.

Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.

Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer.

Tumor chemosensitization strategies based on apoptosis manipulations.

P304

235-247

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/NNM.15.193

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Rammohan Devulapally

P577

2016-01-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

291340967

http://www.w3.org/2001/XMLSchema#string

P698

26787319

http://www.w3.org/2001/XMLSchema#string

P921

P932

4910964

http://www.w3.org/2001/XMLSchema#string